{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:34:16Z","timestamp":1761708856613},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/wnf.0b013e31828740ea","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T22:04:40Z","timestamp":1363989880000},"page":"42-45","source":"Crossref","is-referenced-by-count":24,"title":["Four-Year Follow-Up Study of Pharmacological Treatment in Pathological Gamblers"],"prefix":"10.1097","volume":"36","author":[{"given":"Oded","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limor Klein","family":"Dinur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinhas N.","family":"Dannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/jcp.0b013e31815a4400","article-title":". 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.","volume":"27","author":"Dannon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10550490902787007","article-title":"A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling.","volume":"18","author":"Toneatto","year":"2009","journal-title":"Am J Addict"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v69n0511","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.","volume":"69","author":"Grant","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004850-200109000-00006","article-title":"An open naltrexone treatment study in pathological gambling disorder.","volume":"16","author":"Kim","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004850-200607000-00002","article-title":"Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.","volume":"21","author":"Grant","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/187152710790966696","article-title":"The role of topiramate and other anticonvulsants in the treatment of alcohol dependence: a clinical review.","volume":"9","author":"De Sousa","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/syn.10000","article-title":". Topiramate selectively attenuates nicotine induced increases in monoamine release.","volume":"42","author":"Schiffer","year":"2001","journal-title":"Synapse"},{"issue":"1","key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s002130000665","article-title":"Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment.","volume":"155","author":"Dong","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0278-5846(01)00315-3","article-title":"Alcohol urge and plasma beta-endorphin change after alcohol challenge with naltrexone pretreatment in social drinkers.","volume":"26","author":"Na","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e31828740ea","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:19Z","timestamp":1620976519000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201303000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31828740ea","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}